Traders sold shares of Eli Lilly And Co (NYSE:LLY) on strength during trading on Wednesday. $132.43 million flowed into the stock on the tick-up and $232.90 million flowed out of the stock on the tick-down, for a money net flow of $100.47 million out of the stock. Of all companies tracked, Eli Lilly And Co had the 9th highest net out-flow for the day. Eli Lilly And Co traded up $1.57 for the day and closed at $128.16

LLY has been the topic of several research analyst reports. Barclays reissued a “buy” rating and set a $130.00 price target on shares of Eli Lilly And Co in a report on Sunday, January 20th. BMO Capital Markets increased their price target on Eli Lilly And Co from $124.00 to $132.00 and gave the company an “outperform” rating in a report on Monday, December 24th. They noted that the move was a valuation call. JPMorgan Chase & Co. initiated coverage on Eli Lilly And Co in a report on Tuesday, March 12th. They set an “overweight” rating and a $140.00 price target on the stock. UBS Group initiated coverage on Eli Lilly And Co in a report on Wednesday, January 23rd. They set a “buy” rating and a $131.00 price target on the stock. Finally, Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $128.00 price target on the stock in a report on Wednesday, November 28th. Ten equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $113.06.

The firm has a market capitalization of $129.68 billion, a P/E ratio of 23.09, a price-to-earnings-growth ratio of 2.52 and a beta of 0.33. The company has a quick ratio of 1.38, a current ratio of 1.73 and a debt-to-equity ratio of 1.07.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Wednesday, February 6th. The company reported $1.33 EPS for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The company had revenue of $6.44 billion during the quarter, compared to the consensus estimate of $6.28 billion. During the same period in the prior year, the business posted $1.14 earnings per share. Eli Lilly And Co’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, equities analysts predict that Eli Lilly And Co will post 5.64 EPS for the current year.

In other Eli Lilly And Co news, insider Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $127.01, for a total value of $127,010.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 51,766 shares of the stock in a transaction on Tuesday, January 15th. The stock was sold at an average price of $117.74, for a total value of $6,094,928.84. Following the completion of the sale, the insider now owns 117,963,538 shares of the company’s stock, valued at approximately $13,889,026,964.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 833,190 shares of company stock worth $102,388,102. 0.11% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of the business. Captrust Financial Advisors increased its stake in Eli Lilly And Co by 0.4% in the 4th quarter. Captrust Financial Advisors now owns 21,627 shares of the company’s stock worth $2,503,000 after buying an additional 87 shares in the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in Eli Lilly And Co by 1.6% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 5,543 shares of the company’s stock worth $641,000 after buying an additional 87 shares in the last quarter. First Personal Financial Services increased its stake in Eli Lilly And Co by 2.3% in the 4th quarter. First Personal Financial Services now owns 3,931 shares of the company’s stock worth $455,000 after buying an additional 89 shares in the last quarter. Carroll Financial Associates Inc. increased its stake in Eli Lilly And Co by 1.3% in the 4th quarter. Carroll Financial Associates Inc. now owns 7,029 shares of the company’s stock worth $810,000 after buying an additional 91 shares in the last quarter. Finally, Bailard Inc. increased its stake in Eli Lilly And Co by 3.6% in the 4th quarter. Bailard Inc. now owns 2,672 shares of the company’s stock worth $309,000 after buying an additional 92 shares in the last quarter. Institutional investors and hedge funds own 78.69% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Investors Sell Eli Lilly And Co (LLY) on Strength (LLY)” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.watchlistnews.com/investors-sell-eli-lilly-and-co-lly-on-strength-lly/2905207.html.

Eli Lilly And Co Company Profile (NYSE:LLY)

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: How is the discount rate different from the Federal Funds rate?

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.